Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves Audit LLP as auditor to the Company. The appointment of Kreston Reeves Audit follows a restructuring of the audit practice of Kreston Reeves LLP, the Company’s former auditor, and will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Nuformix appoints Kreston Reeves Audit as new auditor
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Nuformix plc reports statistically significant reductions in TGF-β/SMAD signalling following inhaled administration of NXP002 in a preclinical study, supporting...
Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis,...
Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons....
Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions....
Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the...
Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning....
